HK1226388A1 - 作為tcr-nck相互作用的抑制劑的被醇鹽取代的色烯衍生物 - Google Patents
作為tcr-nck相互作用的抑制劑的被醇鹽取代的色烯衍生物Info
- Publication number
- HK1226388A1 HK1226388A1 HK16114566A HK16114566A HK1226388A1 HK 1226388 A1 HK1226388 A1 HK 1226388A1 HK 16114566 A HK16114566 A HK 16114566A HK 16114566 A HK16114566 A HK 16114566A HK 1226388 A1 HK1226388 A1 HK 1226388A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tcr
- alkoxide
- inhibitors
- derivatives substituted
- chromene derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331542A ES2534318B1 (es) | 2013-10-18 | 2013-10-18 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1226388A1 true HK1226388A1 (zh) | 2017-09-29 |
Family
ID=52016805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16114566A HK1226388A1 (zh) | 2013-10-18 | 2016-12-22 | 作為tcr-nck相互作用的抑制劑的被醇鹽取代的色烯衍生物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10131647B2 (zh) |
| EP (1) | EP3059232B1 (zh) |
| JP (1) | JP6505095B2 (zh) |
| CN (1) | CN105658634B (zh) |
| AU (1) | AU2014335859B2 (zh) |
| CA (1) | CA2925846C (zh) |
| ES (2) | ES2534318B1 (zh) |
| HK (1) | HK1226388A1 (zh) |
| RU (1) | RU2658910C2 (zh) |
| WO (1) | WO2015056085A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534336B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
| WO2017179565A1 (ja) | 2016-04-12 | 2017-10-19 | 日本たばこ産業株式会社 | 香味吸引器 |
| KR20200140262A (ko) * | 2018-02-27 | 2020-12-15 | 아텍스 바이오파마 인코포레이티드 | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032476A1 (en) * | 1997-12-19 | 1999-07-01 | Bayer Corporation | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| DE19858341A1 (de) * | 1998-12-17 | 2000-06-21 | Merck Patent Gmbh | Chromanderivate |
| AU781986B2 (en) | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP4890723B2 (ja) | 2000-07-21 | 2012-03-07 | 中外製薬株式会社 | ＴＮＦαインヒビターとして有用なクマリン誘導体 |
| WO2002092076A1 (en) | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| WO2003062272A1 (es) | 2002-01-24 | 2003-07-31 | Consejo Superior De Investigaciones Científicas | Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck. |
| US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| ES2331451B1 (es) * | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| WO2010009069A1 (en) | 2008-07-16 | 2010-01-21 | Bristol-Myers Squibb Company | Chromene modulators of chemokine receptor activity |
| PL2354134T3 (pl) * | 2008-12-05 | 2016-07-29 | Astellas Pharma Inc | Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny |
| ES2379242B1 (es) | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
| ES2534336B1 (es) | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
-
2013
- 2013-10-18 ES ES201331542A patent/ES2534318B1/es active Active
-
2014
- 2014-10-20 WO PCT/IB2014/002171 patent/WO2015056085A1/es active Application Filing
- 2014-10-20 ES ES14809703T patent/ES2719115T3/es active Active
- 2014-10-20 AU AU2014335859A patent/AU2014335859B2/en active Active
- 2014-10-20 US US15/029,042 patent/US10131647B2/en active Active
- 2014-10-20 JP JP2016522733A patent/JP6505095B2/ja active Active
- 2014-10-20 RU RU2016118037A patent/RU2658910C2/ru active
- 2014-10-20 CN CN201480057192.8A patent/CN105658634B/zh active Active
- 2014-10-20 EP EP14809703.3A patent/EP3059232B1/en active Active
- 2014-10-20 CA CA2925846A patent/CA2925846C/en active Active
-
2016
- 2016-12-22 HK HK16114566A patent/HK1226388A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2719115T3 (es) | 2019-07-08 |
| EP3059232A1 (en) | 2016-08-24 |
| JP2017506209A (ja) | 2017-03-02 |
| EP3059232B1 (en) | 2019-01-09 |
| AU2014335859A1 (en) | 2016-05-05 |
| JP6505095B2 (ja) | 2019-04-24 |
| ES2534318A1 (es) | 2015-04-21 |
| WO2015056085A1 (es) | 2015-04-23 |
| RU2658910C2 (ru) | 2018-06-26 |
| US20160244423A1 (en) | 2016-08-25 |
| RU2016118037A (ru) | 2017-11-23 |
| AU2014335859B2 (en) | 2018-11-01 |
| ES2534318B1 (es) | 2016-01-28 |
| CN105658634B (zh) | 2019-01-22 |
| CA2925846C (en) | 2019-02-19 |
| CA2925846A1 (en) | 2015-04-23 |
| US10131647B2 (en) | 2018-11-20 |
| CN105658634A (zh) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221466A1 (zh) | 作為 抑制劑的聯吡唑衍生物 | |
| HRP20170919T1 (hr) | Novi derivati pirazola | |
| HK1215574A1 (zh) | 作為 -配體的二氮雜哢唑衍生物 | |
| HK1258911A1 (zh) | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 | |
| ZA201602831B (en) | Use of lactones | |
| IL240763A0 (en) | The halopyrazoles as thrombin inhibitors | |
| HK1213566A1 (zh) | 新的四唑酮衍生物 | |
| HK1226388A1 (zh) | 作為tcr-nck相互作用的抑制劑的被醇鹽取代的色烯衍生物 | |
| EP2974723A4 (en) | APPLICATION OF PHTHALIDE COMPOUND | |
| HK1217654A1 (zh) | 作爲激酶抑制劑的呋喃酮化合物 | |
| GB201301975D0 (en) | New method for the purpose of safening |